To explore therapeutic strategies to overcome the resistance of effector T cells toward Treg-mediated suppression in multiple sclerosis (MS) patients, a humanized model based on newborn Rag2−/−γ−/− mice engrafted with CD25-depleted PBMCs from different MS patients was applied (287). This evidence concerns the gene IL2RA and myeloid sarcoma.